MD Acumen · PLAB MLA Mastery Programme
PLAB MLA AKT — Teaching Resources
Official GMC references · 2026-format clinical vignettes · Structured metacognitive reasoning walkthroughs
September 2026 MLA Content Map aligned · AI-generated, clinician-verified · MD ACUMEN LTD
⚠ SEPTEMBER 2026: Major MLA Content Map Transition
From September 2026, all PLAB AKT examinations will be assessed against the updated MLA Content Map — expanding from 311 to approximately 430 core conditions across six clinical domains. The question format shifts to longer clinical vignettes requiring applied reasoning, not factual recall. Study materials published before 2024 will not cover the new conditions or question style. All MD Acumen content is aligned to the September 2026 syllabus.
We don't just tell you the answer. We teach you how to think.
Most question banks tell you which answer is correct and provide a brief rationale. MD Acumen does something fundamentally different: every clinical explanation models the structured metacognitive reasoning process that experienced UK clinicians use instinctively — and that the 2026 MLA is specifically designed to assess.
The explanation is the product. The answer is merely the outcome.
Anchor the Clinical Pattern
Before reading the options, identify the dominant clinical pattern from the vignette. What illness script does this trigger? Which system is involved? What is the likely category of diagnosis? This step mirrors how an experienced GP reads a patient's presentation in the first 30 seconds of a consultation.
Identify the Discriminating Features
Which details in the vignette narrow the differential? Age, risk factors, investigation results, drug history, examination findings — each element is placed there deliberately by the question writer to distinguish the correct answer from plausible distractors. What separates this presentation from similar-looking alternatives?
Eliminate Unsafe or Implausible Distractors
Before selecting the correct answer, systematically exclude options that are clinically unsafe, temporally inappropriate, or diagnostically premature. Distractor analysis is a learnable skill — the MLA tests whether you can recognise why the wrong answers are wrong, not just why the right answer is right.
Apply the Guideline Framework
Confirm the answer against the relevant UK guideline — NICE, CKS, BNF, or SIGN. The MLA is a UK licensing examination: the correct answer is always the answer that current UK guidelines support, even where international guidance may differ. This step ensures your answer is defensible, not just intuitive.
Confirm and Commit
Re-read the lead-in question. Does your selected answer directly address what is being asked — the next investigation, the most appropriate management, the most likely diagnosis? Many candidates select a clinically reasonable answer that does not answer the specific question asked. The final check prevents this error.
Anatomy of a 2026 PLAB MLA Clinical Vignette
Understanding how each component is structured — and what it tests.
Patient Demographics
Age, gender, ethnicity, occupation — sets the baseline risk profile and primes the differential diagnosis from the outset. A 72-year-old smoker and a 24-year-old athlete with identical chest pain trigger entirely different illness scripts.
Presenting Complaint & History
The clinical hook — chief symptom, onset, duration, severity. Followed by PMH, drug history, social history, family history. Every detail is layered deliberately to add or exclude differentials. Nothing in a well-written vignette is irrelevant.
Examination & Investigations
Vital signs (ABCDE approach), targeted examination findings, bedside tests, bloods, imaging. The 2026 format tests interpretation in clinical context, not in isolation. An elevated troponin means different things in different vignettes.
GMC Resources & Exam Guidance
MLA Content Map
Updated September 2026 syllabus — 430 conditions across six domains
PLAB and the MLA
GMC guidance on how PLAB aligns with the Medical Licensing Assessment
PLAB 1 AKT — Example Questions
Official GMC example question set with answer sheet (PDF)
PLAB Misconduct Procedures
GMC examination conduct rules and consequences of misconduct
Sample Questions with Structured Reasoning Walkthroughs
Full-length exemplars demonstrating the clinical reasoning depth that the September 2026 MLA demands — with the MD Acumen Five-Step Metacognitive Technique applied to each.
Obstetrics & Gynaecology 2026 Format
Women's Health: HRT & Breakthrough Bleeding
Clinical Vignette: A 54-year-old woman presents to her GP with a 3-week history of unscheduled breakthrough vaginal bleeding. She has been on continuous combined HRT for six months. She admits non-compliance with the progestogen component for two months (unopposed oestrogen only). BMI 41, well-controlled hypertension, never had a cervical smear test. No cervical or vaginal pathology on examination. Pelvic ultrasound: endometrial thickness 9mm.
What is the most appropriate next investigation?
A Repeat pelvic ultrasound in 3 months
Incorrect. Watchful waiting with a thickened endometrium (9mm) in the context of unopposed oestrogen and BMI 41 would delay the diagnosis of potential endometrial hyperplasia or malignancy. This is a patient safety failure — the risk factors mandate tissue diagnosis now, not re-imaging later.
B High-vaginal and endocervical swabs
Incorrect. Swabs assess for infection, which is not the clinical concern here. The vignette states no cervical or vaginal pathology on examination. The constellation of risk factors (unopposed oestrogen, obesity, thickened endometrium) points to an endometrial process requiring tissue sampling, not infection screening.
C Pipelle endometrial biopsy ✓
Correct.
Step 1 — Anchor the pattern: Postmenopausal woman + unscheduled bleeding + unopposed oestrogen + obesity. This illness script triggers "endometrial hyperplasia / malignancy until proven otherwise."
Step 2 — Discriminating features: Two months of unopposed oestrogen (progestogen non-compliance) is the critical detail. BMI 41 is an independent risk factor for endometrial cancer. Endometrial thickness 9mm exceeds the 4mm threshold for investigation in postmenopausal bleeding. Every element converges on the same diagnosis.
Step 3 — Eliminate distractors: Ultrasound repeat (A) delays diagnosis — unsafe. Swabs (B) address infection, not the clinical concern. Reassurance (D) in a high-risk patient is clinically indefensible. Hysterectomy referral (E) is premature without tissue diagnosis.
Step 4 — Guideline confirmation: NICE NG88 (heavy menstrual bleeding) and CKS guidance on postmenopausal bleeding recommend endometrial biopsy when endometrial thickness exceeds 4mm in the presence of unscheduled bleeding. Pipelle biopsy is the first-line tissue sampling technique in primary care / outpatient gynaecology.
Step 5 — Confirm the lead-in: "Most appropriate next investigation" — Pipelle is the immediate next diagnostic step. It is minimally invasive, can be performed in an outpatient setting, and provides the tissue diagnosis required before any management decision.
D Reassurance and adjustment of HRT dose
Incorrect. Reassurance would be clinically unsafe. This patient has three independent risk factors for endometrial hyperplasia/carcinoma (unopposed oestrogen, BMI >40, thickened endometrium). Adjusting the HRT dose addresses the future prescription but does not investigate the current bleeding episode. The priority is tissue diagnosis.
E Hysterectomy referral
Incorrect. Hysterectomy may ultimately be appropriate depending on histology results, but referring for surgery without first establishing a tissue diagnosis is premature and does not reflect the stepwise diagnostic approach. Pipelle biopsy must precede any surgical decision.
Original question by MD Acumen — not recalled exam material.
Respiratory 2026 Format
Primary Care: COPD Step-Up Management
Clinical Vignette: A 72-year-old man with a 10-year history of COPD presents with worsening breathlessness. MRC dyspnoea score 3. One exacerbation requiring oral steroids in the past 12 months. Currently on LAMA monotherapy. Blood eosinophils 350 cells/µL. CXR normal. BMI 24. Using salbutamol rescue inhaler four times daily. Inhaler technique assessed and excellent.
What is the most appropriate next pharmacological step?
A Add extra SABA only
Incorrect. The patient is already using SABA four times daily — indicating inadequate symptom control on current therapy. Adding more SABA does not address the underlying disease progression and does not reduce exacerbation risk. This is a step-up trigger, not a SABA optimisation opportunity.
B Start Prednisolone and Amoxicillin
Incorrect. This is the treatment for an acute exacerbation. The vignette describes chronic progressive symptoms, not an acute infective episode. There is no mention of increased sputum volume, purulence, or acute deterioration. Treating a chronic management question with acute therapy is a common distractor trap.
C Switch to triple therapy (ICS/LABA/LAMA) ✓
Correct.
Step 1 — Anchor the pattern: COPD + persistent symptoms despite monotherapy + exacerbation history + raised eosinophils. This is a chronic management step-up question, not an acute presentation.
Step 2 — Discriminating features: Blood eosinophils 350 cells/µL is the critical discriminator. NICE NG115 and GOLD 2024 identify eosinophils ≥300 as a "treatable trait" predicting ICS responsiveness. One exacerbation + persistent symptoms on monotherapy = step-up trigger. The eosinophil count determines which step-up pathway.
Step 3 — Eliminate distractors: Extra SABA (A) is not a step-up. Acute treatment (B) is temporally inappropriate. LTOT (D) requires specific criteria (PaO2 ≤7.3 kPa) not met here. Roflumilast (E) is reserved for severe COPD with FEV1 <50% and frequent exacerbations — this patient does not meet those criteria.
Step 4 — Guideline confirmation: NICE NG115 recommends: if on LAMA monotherapy with persistent symptoms + exacerbations + eosinophils ≥300 → escalate to ICS/LABA/LAMA triple therapy. GOLD 2024 concurs: eosinophils ≥300 + exacerbation history = ICS-containing regimen for mortality and exacerbation reduction benefit.
Step 5 — Confirm the lead-in: "Most appropriate next pharmacological step" — triple therapy is the guideline-supported escalation. It is pharmacological (not a referral), it is the next step (not a distant option), and it directly addresses both symptom burden and exacerbation risk.
D Refer for LTOT assessment
Incorrect. Long-term oxygen therapy requires specific criteria: PaO2 ≤7.3 kPa on two occasions measured in a clinically stable state. The vignette describes "mild hypoxia" with salbutamol use but does not describe criteria meeting the LTOT threshold. Pharmacological optimisation should precede referral for oxygen assessment.
E Add Roflumilast
Incorrect. Roflumilast (a PDE4 inhibitor) is reserved for patients with severe COPD (FEV1 <50% predicted), a chronic bronchitis phenotype, and frequent exacerbations despite triple therapy. This patient has not yet been escalated from monotherapy. Jumping to Roflumilast skips multiple guideline-recommended steps.
Original question by MD Acumen — not recalled exam material.
Cardiovascular 2026 Format
Primary Care: Hypertension First-Line Treatment
Clinical Vignette: A 58-year-old Afro-Caribbean woman is diagnosed with stage 1 hypertension following ABPM confirmation (average daytime reading 148/92 mmHg). She has type 2 diabetes managed with metformin. eGFR 64, urine ACR 4.2 mg/mmol (microalbuminuria). No history of cardiovascular events. BMI 31. Non-smoker.
What is the most appropriate first-line antihypertensive?
A Amlodipine 5mg
Incorrect. Amlodipine (a CCB) would be the first-line choice for Afro-Caribbean patients without diabetes or CKD with albuminuria. However, this patient has both diabetes and microalbuminuria — these comorbidities override the ethnicity-based pathway and mandate an ACE inhibitor for its renoprotective effect.
B Ramipril 2.5mg ✓
Correct.
Step 1 — Anchor the pattern: New hypertension + type 2 diabetes + microalbuminuria + Afro-Caribbean ethnicity. This is a first-line antihypertensive selection question where comorbidities compete with ethnicity-based guidance.
Step 2 — Discriminating features: The ACR of 4.2 mg/mmol confirms microalbuminuria (threshold: ≥3 mg/mmol). In the presence of diabetes and albuminuria, NICE NG136 mandates an ACE inhibitor regardless of age or ethnicity — the renoprotective benefit overrides the standard A/B vs C/D pathway. This is the discriminator the question is testing.
Step 3 — Eliminate distractors: Amlodipine (A) would be correct for Afro-Caribbean ethnicity without diabetes/albuminuria — a classic distractor designed to catch candidates who apply the ethnicity rule without checking for comorbidities. Indapamide (C) is a thiazide-like diuretic, appropriate as step 2, not step 1 with albuminuria. Atenolol (D) is no longer first-line for hypertension. Doxazosin (E) is step 4 resistant hypertension.
Step 4 — Guideline confirmation: NICE NG136 (2019, updated 2022): offer an ACE inhibitor to people with type 2 diabetes and an ACR ≥3 mg/mmol. This overrides the standard ethnicity-based pathway (which would otherwise direct towards a CCB). NICE CKD guideline (NG203) reinforces ACE inhibitor use in diabetic nephropathy.
Step 5 — Confirm the lead-in: "Most appropriate first-line antihypertensive" — Ramipril is the correct first-line choice. It addresses hypertension, provides renoprotection in diabetic nephropathy, and is guideline-concordant for this specific clinical combination.
C Indapamide 2.5mg
Incorrect. Indapamide is a thiazide-like diuretic used as step 2 add-on therapy in the NICE hypertension pathway, or as first-line in specific scenarios. It does not provide the renoprotective benefit required by this patient's microalbuminuria and diabetes combination.
D Atenolol 50mg
Incorrect. Beta-blockers are no longer recommended as first-line antihypertensives in NICE NG136. Atenolol may be considered for hypertension with concurrent heart failure or post-MI, but this patient has neither. This is a legacy distractor that tests whether candidates are using current guidance.
E Doxazosin 4mg
Incorrect. Doxazosin (an alpha-blocker) is a step 4 agent for resistant hypertension. Offering it as first-line therapy bypasses three steps of the NICE pathway and is inappropriate at this stage of management.
Original question by MD Acumen — not recalled exam material.
The pedagogic science behind the five-step technique
Illness Scripts (Schmidt & Rikers)
Expert clinicians develop structured mental representations of diseases. Step 1 trains candidates to activate the correct illness script before looking at the options — reducing the cognitive load of distractor analysis and improving diagnostic accuracy.
Distractor Analysis (Ericsson)
Deliberate practice of distractor elimination builds the expert reasoning that distinguishes top candidates. Understanding why each wrong answer is wrong develops transferable clinical reasoning — not just familiarity with one question.
Guideline Anchoring (UK-Specific)
The MLA is a UK licensing examination. International candidates must learn that the correct answer is always the NICE/CKS/BNF-supported answer — even where their home country's protocols differ. Step 4 embeds this habit from the first question attempted.
Lead-In Discipline (Metacognition)
Step 5 is the error-prevention mechanism that most question banks never teach. Re-reading the lead-in question catches the single most common reason candidates select wrong answers: choosing a clinically reasonable option that does not answer the specific question asked.
Learn the technique that changes how you think
The MD Acumen PLAB MLA Mastery Programme teaches the five-step metacognitive reasoning technique across 12 live tutorial sessions, 36 contact hours, and an AI-powered adaptive question bank — launching 1 July 2026.
Legal & Disclaimer · enquiry@mdacumen.com